Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dna X (SONM) Other Operating Expenses (2018 - 2025)

Historic Other Operating Expenses for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $2.5 million.

  • Dna X's Other Operating Expenses fell 1947.45% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 613.02%. This contributed to the annual value of $16.4 million for FY2024, which is 8734.03% up from last year.
  • Per Dna X's latest filing, its Other Operating Expenses stood at $2.5 million for Q3 2025, which was down 1947.45% from $3.4 million recorded in Q2 2025.
  • Dna X's 5-year Other Operating Expenses high stood at $6.4 million for Q2 2024, and its period low was $730000.0 during Q3 2022.
  • For the 5-year period, Dna X's Other Operating Expenses averaged around $3.0 million, with its median value being $3.0 million (2024).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first plummeted by 8199.31% in 2022, then skyrocketed by 25227.15% in 2024.
  • Quarter analysis of 5 years shows Dna X's Other Operating Expenses stood at $4.7 million in 2021, then plummeted by 67.68% to $1.5 million in 2022, then surged by 100.72% to $3.1 million in 2023, then skyrocketed by 62.8% to $5.0 million in 2024, then crashed by 50.63% to $2.5 million in 2025.
  • Its Other Operating Expenses stands at $2.5 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.2 million for Q1 2025.